AG
DSGN icon

Algert Global’s Design Therapeutics DSGN Stock Holding History

Algert Global’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.28M Buy
296,085
+91,346
+45% +$1.14M 0.05% 597
2026
Q1 		$2.18M Buy
204,739
+16,970
+9% +$172K 0.03% 696
2025
Q4 		$1.76M Buy
+187,769
New +$1.47M 0.03% 736
2025
Q1 		– Sell
-16,238
Closed -$100K – 1213
2024
Q4 		$100K Buy
16,238
+1,860
+13% +$10.8K ﹤0.01% 1120
2024
Q3 		$77.4K Buy
14,378
+1,962
+16% +$9.23K ﹤0.01% 1130
2024
Q2 		$41.6K Buy
12,416
+1,336
+12% +$5.21K ﹤0.01% 1450
2024
Q1 		$44.7K Sell
11,080
-24,540
-69% -$65.5K ﹤0.01% 1036
2023
Q4 		$94.4K Hold
35,620
– – ﹤0.01% 1080
2023
Q3 		$84.1K Buy
35,620
+16,190
+83% +$75.5K ﹤0.01% 1042
2023
Q2 		$122K Buy
+19,430
New +$119K 0.01% 1028

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Algert Global's DSGN Position: Q2 2026 in Review

Algert Global increased its Design Therapeutics (DSGN) stake by 45% in Q2 2026, buying an estimated $1.14M and bringing the position to 296,085 shares worth $4.28M. The position accounts for 0.05% of the portfolio, ranked #597.

Algert Global first reported a position in DSGN in Q2 2023 and has held it in 10 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Algert Global held 296,085 shares of Design Therapeutics worth $4.28M as of Q2 2026.
  • Algert Global bought 91,346 Design Therapeutics shares in Q2 2026, an estimated $1.14M.
  • Design Therapeutics made up 0.05% of Algert Global's portfolio in Q2 2026, its #597 holding.
  • Algert Global first reported a position in Design Therapeutics in Q2 2023 and has held it in 10 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.